An assessment of the first 3 years' use of Implanon in Luton.
OBJECTIVE
Implanon was introduced in the UK in September 1999. We present here the results of our first 106 Implanon insertions, performed over a period of 18 months. The aims of the study were to study the clinical and demographic profile of Implanon users, to assess the continuation rates of Implanon in the local population, and to identify the reasons for removal.


METHODS
This was a case note-based study in which the data were transferred to a standardised pre-tested proforma.


RESULTS
The age range of the 106 Implanon users was 15-43 years. Eighty-six of these clients had their Implanon removed and the Implanon status of 20 clients is not known since they were lost to follow-up by our service. Of these 86 cases, 26 had completed the full 3-year period; therefore, the continuation rate at 3 years was 30.2%. The continuation rate at the end of 1 year was 69.8% and at 2 years was 44.1%. Of the 60 women who had their Implanon removed before the recommended 3-year period, the most common reason was for bleeding irregularity (24 cases, 40%).


CONCLUSIONS
This is the first published study set in the UK within a real-life setting to follow up a cohort of Implanon users for the full 3-year period. No contraceptive failures were found, replicating previous clinical trials. The continuation rate in this real-life situation was quite low compared to clinical trials. This is frequently the case when comparing real-life situations with clinical trials and may be in part due to higher motivation on the part of clinical trial participants.
Agrawal
Anjali
A
South East Hertfordshire Primary Care Trust, Welwyn Garden City, UK. anjaliagrawala@hotmail.com
Robinson
Christine
C
D000293:Adolescent; D000328:Adult; D003268:Contraception Behavior / Q000706:statistics & numerical data*; D003280:Contraceptives, Oral, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003376:Counseling; D017135:Desogestrel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D020878:Device Removal; D004343:Drug Implants / Q000009:adverse effects; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D011446:Prospective Studies; D018570:Risk Assessment; D013997:Time Factors; D016896:Treatment Outcome; D006113:United Kingdom
D003280:Contraceptives, Oral, Synthetic; D004343:Drug Implants; C044815:etonogestrel; D017135:Desogestrel